MAIA PE Ratio & Valuation, Is MAIA Overvalued

Historical Valuation

Maia Biotechnology Inc (MAIA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.51. The fair price of Maia Biotechnology Inc (MAIA) is between NaN to NaN according to relative valuation method.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.50

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Maia Biotechnology Inc (MAIA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Maia Biotechnology Inc (MAIA) has a current Price-to-Book (P/B) ratio of 1323.41. Compared to its 3-year average P/B ratio of 115.83, the current P/B ratio is approximately 1042.52% higher. Relative to its 5-year average P/B ratio of 95.66, the current P/B ratio is about 1283.41% higher. Maia Biotechnology Inc (MAIA) has a Forward Free Cash Flow (FCF) yield of approximately -25.70%. Compared to its 3-year average FCF yield of -35.32%, the current FCF yield is approximately -27.25% lower. Relative to its 5-year average FCF yield of -33.35%, the current FCF yield is about -22.96% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for MAIA competitors is 45.47, providing a benchmark for relative valuation. Maia Biotechnology Inc Corp (MAIA.A) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of MAIA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of MAIA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is MAIA currently overvalued or undervalued?

What is Maia Biotechnology Inc (MAIA) fair value?

MAIA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Maia Biotechnology Inc (MAIA) is between NaN to NaN according to relative valuation method.

How does MAIA's valuation metrics compare to the industry average?

The average P/S ratio for MAIA's competitors is 45.47, providing a benchmark for relative valuation. Maia Biotechnology Inc Corp (MAIA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Maia Biotechnology Inc (MAIA) as of Mar 12 2026?

As of Mar 12 2026, Maia Biotechnology Inc (MAIA) has a P/B ratio of 1323.41. This indicates that the market values MAIA at 1323.41 times its book value.

What is the current FCF Yield for Maia Biotechnology Inc (MAIA) as of Mar 12 2026?

As of Mar 12 2026, Maia Biotechnology Inc (MAIA) has a FCF Yield of -25.70%. This means that for every dollar of Maia Biotechnology Inc's market capitalization, the company generates -25.70 cents in free cash flow.

What is the current Forward P/E ratio for Maia Biotechnology Inc (MAIA) as of Mar 12 2026?

As of Mar 12 2026, Maia Biotechnology Inc (MAIA) has a Forward P/E ratio of -2.32. This means the market is willing to pay $-2.32 for every dollar of Maia Biotechnology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Maia Biotechnology Inc (MAIA) as of Mar 12 2026?

As of Mar 12 2026, Maia Biotechnology Inc (MAIA) has a Forward P/S ratio of 0.00. This means the market is valuing MAIA at $0.00 for every dollar of expected revenue over the next 12 months.

MAIA Valuation